Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.99USD
18 May 2018
Change (% chg)

$0.02 (+2.06%)
Prev Close
$0.97
Open
$1.00
Day's High
$1.00
Day's Low
$0.97
Volume
8,218
Avg. Vol
53,774
52-wk High
$2.83
52-wk Low
$0.78

Chart for

About

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $19.05
Shares Outstanding(Mil.): 21.55
Dividend: --
Yield (%): --

Financials

  DMPI.OQ Industry Sector
P/E (TTM): -- 8.60 20.18
EPS (TTM): -0.85 -- --
ROI: -992.44 16.00 0.48
ROE: -- 19.38 15.39

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

17 Apr 2018

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

13 Apr 2018

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

14 Feb 2018

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

26 Dec 2017

Competitors

  Price Chg
Gilead Sciences, Inc. (GILD.OQ) $68.02 +0.42
Celgene Corporation (CELG.OQ) $78.37 -1.61
Exelixis, Inc. (EXEL.OQ) $21.58 +0.02

Earnings vs. Estimates